A disease-reversing cure for Alzheimer's disease receives FDA approval before 2035.

Question

Six frontier AI models put this at 10% by 1 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

10% — the median of 6 frontier models, resolving by 2036-10-01.

Answer

Gemini (Google): 6% — Reversing established neurodegeneration requires cellular repair that has never succeeded in late-stage human trials. No candidate currently in Phase 2 or 3 clinical pipelines demonstrates genuine cognitive reversal rather than slowed decline. FDA approval before 2035 requires a successful Phase 3 readout by 2033, leaving insufficient time for unproven regenerative modalities. A Phase 2 trial demonstrating sustained, statistically significant cognitive improvement on ADAS-Cog would sharply raise these odds.

Answer

Claude (Anthropic): 6% — Hinges on a genuine disease-reversing (not just slowing) therapy clearing Phase 3 and FDA review by 2035. Current approved drugs (lecanemab, donanemab) only modestly slow decline, not reverse pathology or cognition, showing how hard reversal is biologically. Drug development timelines mean any reversal-class candidate not already in late Phase 3 today is unlikely to reach approval before 2035. No current pipeline candidate has shown true cognitive reversal in trials; a dramatic Phase 2/3 reversal readout would be the main thing to change this.

Answer

GPT (OpenAI): 12% — It hinges on whether an amyloid/tau or novel target can show durable cognitive restoration in large Phase 3 trials. FDA approvals through 2026, including lecanemab and donanemab, slow decline modestly rather than restore lost cognition. A sponsor must complete Phase 3 efficacy, safety, and confirmatory review by roughly 2034; CNS trials commonly fail or take years. I would raise this sharply if a Phase 2 trial showed replicated, multi-year cognitive improvement plus biomarker reversal.

Answer

Grok (xAI): 18% — Reversal or full halt of AD pathology plus cognition needs a new mechanism past anti-amyloid, with Phase 3 data in ~6 years. FDA approval before 2035 requires a sponsor to file after successful Phase 3 by ~2033; typical AD programs take 8–12 years from first-in-human. Historic AD Phase 3 success rate is <2% and no approved agent has halted or reversed cognition; anti-amyloid antibodies only slow decline ~30%. A 2027–28 Phase 2 readout showing actual cognitive recovery (not just biomarker clearance) would raise the odds most.

Answer

DeepSeek (DeepSeek): 12% — This turns on whether anti-amyloid or anti-tau drugs can show reversal, not just slowing, in a pivotal trial by ~2032. Lecanemab and donanemab (2023-2024 approvals) slow decline ~27-35% but reverse nothing; no approved drug meets the 'reversing' bar today. The FDA needs a phase 3 readout showing halted or improved cognition, which realistically requires a trial finishing by ~2032 for approval before 2035. Base rate for a genuinely disease-reversing neurodegenerative approval in a decade is very low; anti-amyloid antibodies have repeatedly failed to reverse, though tau or…

Answer

Qwen (Alibaba): 7% — A disease-reversing cure requires clearing pathology AND restoring lost cognition—no candidate has shown reversal in Phase 3. Current approved drugs (lecanemab, donanemab) slow decline ~27-35% but don't reverse; no Phase 2/3 agent has demonstrated cognitive recovery, and the pipeline is 5-10+… FDA approval of a novel mechanism typically takes 8-12 years from Phase 1; even if a breakthrough candidate entered trials today, Phase 3 completion plus review would… A development that would raise this: a Phase 2 readout showing statistically significant cognitive improvement (not just slowed decline) in a biomarker-confirmed AD…

A disease-reversing cure for Alzheimer's disease receives FDA approval before 2035.

A clinically proven cure for dementia is approved before 2032.

A definitive cure for at least five major cancers is approved within 10 years.

A definitive cure for cancer is developed and approved within 20 years.

An FDA-approved universal cure for all major forms of cancer is available before 2035.